Literature DB >> 7416888

Haemodynamic and electrophysiologic actions of alinidine in the dog.

W Traunecker, A Walland.   

Abstract

Alinidine (St 567, 2-[N-allyl-N-(2,6-dichlorophenyl)-amino]-2-imidazoline), the N-allyl derivative of clonidine which causes a specific bradycardia at the sinus node, has been investigated for cardiovascular effects. In a total of 7 mongrel dogs anaesthetized with piritramide and respirated with nitrous oxide 1.5 mg/kg alinidine was injected intravenously and 2 hr later, long before subsidence of the effects, a further dose of 3 mg/kg was given. Heart rate was reduced by both doses (-38, -50% of control) while arterial blood pressure decreased slightly only with 3 mg/kg (-13%). Cardiac output (thermodilution) was diminished (-33, -54%) and total peripheral resistance increased (+48, +101%). Simultaneously contractility (dp/dtmax.; -27, -46%), cardiac volume work (-34, -60%), tension time index (-23, -38%) and coronary sinus blood flow (electromagnetic flowmeter) decreased (-22, -48%). These results suggest a reduction in myocardial oxygen demand as is confirmed by the detection of reduced myocardial oxygen consumption (-14, -44%). Oxygen content of the coronary venous blood remained unchanged. In contrast to cardiac output and femoral artery flow (-37, -37%) renal blood flow was not affected. In another group of 9 dogs anaesthetized with pentobarbitone His bundle EG and ECG were reported. Alinidine (1.5 mg/kg i.v.) prolonged the A-H interval under spontaneous contraction (+65%) as well as at atrial pacing with 120 stimuli/min (+64%), thus pointing to a retarded AV conduction. Two hr after the drug administration bradycardia and A-H prolongation were still fully developed. The intervals P-A, H-V and the QRS complex were not influenced. In 4 further dogs atrial pacing rate was increased in stages up to 300 stimuli/min and the maximal ventricular follow frequency determined. Alinidine (1.5 mg/kg i.v.) reduced the maximal follow frequency from 215 to 125 beats/min (-43%). This effect is considered as a consequence of the retarded conduction in the AV node.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7416888

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  10 in total

1.  Antiischemic effects of alinidine in paced isolated rat hearts.

Authors:  I Streller; A Walland
Journal:  Basic Res Cardiol       Date:  1990 Jan-Feb       Impact factor: 17.165

2.  Mechanisms of chronotropic cardiac effects of alinidine and plasma concentration-response relationships in the conscious dog with chronic atrioventricular block.

Authors:  M Boucher; E Chapuy; M A Lefebvre; A Mignot; P Duchêne-Marullaz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

3.  Proof of the linearity of the pharmacokinetics of alinidine in man.

Authors:  D Arndts; H Warnkross; K L Rominger; H Justus
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats.

Authors:  W D Bechtel; I Richter
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

5.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

6.  Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome.

Authors:  B Stanek; W Reiterer; P Placheta; G Raberger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs.

Authors:  D Arndts; G Leb; H J Förster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

8.  Comparative effects of alinidine and propranolol in ischaemic heart disease.

Authors:  J Schurmans; J Piessens; H Kesteloot; H De Geest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 9.  HCN channels and heart rate.

Authors:  Pietro Scicchitano; Santa Carbonara; Gabriella Ricci; Cosimo Mandurino; Manuela Locorotondo; Gabriella Bulzis; Michele Gesualdo; Annapaola Zito; Rosa Carbonara; Ilaria Dentamaro; Graziano Riccioni; Marco Matteo Ciccone
Journal:  Molecules       Date:  2012-04-05       Impact factor: 4.411

10.  Characterization of drug binding within the HCN1 channel pore.

Authors:  Jérémie Tanguay; Karen M Callahan; Nazzareno D'Avanzo
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.